Japan’s Sawai Files For ANDA Of Generic Pitavastatin In U.S.
This article was originally published in PharmAsia News
Executive Summary
Sawai has filed an abbreviated new drug application for their generic HMG-CoA reductase inhibitor pitavastatin (Livalo) in the U.S. through its subsidiary in Delaware, the company announced on June 16.